According to a recent LinkedIn post from Okami Medical, clinicians recently used the company’s LOBO device in a high‑risk case involving a 28‑year‑old patient who was 27 weeks pregnant with bilateral pulmonary aneurysms. The post describes a multidisciplinary setting with continuous fetal monitoring and highlights rapid occlusion of aneurysm flow within two minutes using three LOBO implants and the SENDERO MAX system.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The company’s LinkedIn post highlights use of multiple LOBO sizes to treat separate feeder arteries in both lungs, suggesting versatility of the platform in complex vascular anatomies. For investors, this type of real‑world, high‑acuity case exposure could support physician adoption, strengthen clinical credibility in interventional radiology, and potentially drive incremental procedure volumes in the pulmonary and aneurysm‑management segments.
The post suggests that demonstrating effectiveness in urgent, maternal‑fetal scenarios may enhance Okami Medical’s differentiation against competing embolization technologies. If similar outcomes are replicated and documented in broader case series or formal studies, the company could gain leverage in hospital value analyses, support reimbursement discussions, and enhance its competitive positioning within the MedTech embolization market.